NeoContact is the trade name and generic name for Compound Pseudoephedrine Hydrochloride Extended-Release Capsules, which is recommended for pregnant women because of the high sensitization of the fetus to this medication, but it is not prohibited.
Pseudoephedrine Hydrochloride Extended-Release Capsules contain ephedrine and chlorpheniramine maleate, both of which may affect the development of respiratory function in children.
Ephedrine belongs to a kind of anesthetic drug, which may cause fetal growth and development, and may even cause fetal deformity when used during pregnancy; Chlorpheniramine maleate belongs to a kind of antiallergic drug, which may cause fetal deformity and growth and developmental retardation when taken by pregnant women.
Common adverse effects of Pseudoephedrine Hydrochloride Extended-Release Capsules include dizziness, dry mouth, drowsiness, and weakness, etc. It is contraindicated in patients with severe coronary artery disease, psychiatric disorders, and severe hypertension.
In addition, the use of compound pseudoephedrine hydrochloride extended-release capsules has certain risks, patients need to get the guidance of a specialist.